Shares of electroCore, Inc. (NASDAQ:ECOR - Get Free Report) traded down 2% during trading on Thursday . The company traded as low as $18.28 and last traded at $18.99. 168,401 shares were traded during trading, an increase of 71% from the average session volume of 98,745 shares. The stock had previously closed at $19.37.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright increased their price objective on shares of electroCore from $22.00 to $25.00 and gave the company a "buy" rating in a report on Wednesday, December 18th.
Read Our Latest Research Report on ECOR
electroCore Stock Performance
The stock has a 50 day moving average price of $16.37 and a 200 day moving average price of $11.35. The company has a market cap of $126.40 million, a P/E ratio of -10.38 and a beta of 0.48.
Institutional Trading of electroCore
Hedge funds and other institutional investors have recently made changes to their positions in the business. JPMorgan Chase & Co. increased its holdings in shares of electroCore by 31,250.0% in the fourth quarter. JPMorgan Chase & Co. now owns 3,762 shares of the company's stock valued at $61,000 after buying an additional 3,750 shares in the last quarter. DnB Asset Management AS bought a new position in electroCore during the fourth quarter valued at approximately $180,000. HighTower Advisors LLC acquired a new position in electroCore during the third quarter worth $255,000. NewEdge Advisors LLC bought a new position in shares of electroCore in the 4th quarter valued at approximately $274,000. Finally, Jane Street Group LLC acquired a new stake in shares of electroCore in the fourth quarter worth $278,000. 26.74% of the stock is currently owned by institutional investors.
electroCore Company Profile
(
Get Free Report)
electroCore, Inc, a commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally. The company is developing gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider electroCore, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and electroCore wasn't on the list.
While electroCore currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
